Intestinibacter bartlettii is a Gram-positive, obligate anaerobic, spore-forming bacterium within the Firmicutes phylum. It is a relatively understudied gut commensal that has recently appeared in Mendelian randomization and metagenomic studies with contradictory associations -- protective against cardiovascular disease but a causal risk factor for colorectal cancer.
Spore-Forming Biology
- I. bartlettii produces endospores, enabling survival during oxygen exposure, antibiotic treatment, and environmental stress.
- Spore formation may explain its persistence in disease states where other obligate anaerobes are depleted.
- Reclassified from Clostridium bartlettii; the genus Intestinibacter was established to reflect its distinct phylogenetic position.
Cardiovascular Disease: Protective Role
Bidirectional Mendelian randomization provides causal evidence for a protective effect of Intestinibacter against multiple CVD outcomes [dai 2024 gut microbiota cvd bidirectional mr]:
- Protective against atrial fibrillation (OR=0.908)
- Protective against coronary artery disease (OR=0.919)
- Grouped with other butyrate producers (Coprococcus, Ruminiclostridium) as metal-sensitive protective taxa.
- These protective taxa are among those most susceptible to depletion by heavy metals exposure, suggesting that metal-induced dysbiosis could remove CVD protection.
Colorectal Cancer: Risk Factor
In contrast to its CVD-protective role, MR evidence identifies Intestinibacter as a causal risk factor for CRC [xiang 2023 host gene microbiome crc mr]:
- Strongest individual CRC risk effect among tested genera (OR=1.31, P=0.0038).
- Replicated in independent FinnGen validation cohort.
- Meta-analysis combining AGWAS and FinnGen confirmed the causal association.
- This paradox -- protective in CVD but harmful in CRC -- may reflect tissue-specific effects of its metabolic products or spore-mediated immune modulation.
Metabolic and Dietary Associations
- Decreased by metformin treatment in type 2 diabetes patients, alongside broader shifts in gut microbiome composition [wu 2017 metformin gut microbiome t2d nature medicine].
- Linked to starch degradation pathways in the context of functional diet studies of multiple sclerosis, where I. bartlettii was associated with dietary fiber metabolism [gutmann 2025 functional microbiome diet ms].
Context-Dependent Nature
The opposing CVD and CRC associations of Intestinibacter exemplify a broader principle: single gut taxa can have tissue- and disease-specific effects that defy simple classification as beneficial or harmful. Its spore-forming capacity, metabolic versatility, and responsiveness to both diet and medication make it a genus warranting deeper functional characterization.
Connections
- cardiovascular disease -- MR-identified protective factor against AF and CAD
- colorectal cancer -- MR-identified causal risk factor with the strongest effect size
- short chain fatty acids -- butyrate production underlies CVD-protective mechanism
- heavy metals -- classified among metal-sensitive butyrate producers vulnerable to depletion
- dysbiosis -- metformin decreases Intestinibacter; dietary fiber supports it
- multiple sclerosis -- linked to starch degradation in dietary MS studies
- selenium -- selenium status may modulate its protective CVD effects